Commercial Launch of Rapid Diagnostic Device for Multiple Myeloma

Abingdon Health Ltd announces the commercial launch of Seralite® - FLC the world’s first rapid diagnostic device for multiple myeloma


Newswise — Seralite® - FLC is a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum as an aid to the diagnosis and management of multiple myeloma. The assay provides an accurate picture of disease status in 10 minutes. Using a simple to use, portable, rapid test, clinicians are able to monitor patients in “real time” supporting faster decision making.

The features of the Seralite®- FLC device provide immediate and empowering benefits to clinicians and laboratory professionals. By obtaining results rapidly, clinicians are able to better understand disease status and can make informed treatment decisions quickly and efficiently.

Use of Seralite® - FLC can facilitate:• Reduced waiting time for results• Earlier diagnosis for improved patient outcome• Fewer clinic visits• Peace of mind for patient

To read more technical information please click on this link to view thefull Seralite® - FLC press release.

***Not for sale in the USA***

  • share-facebook-Commercial Launch of Rapid Diagnostic Device for Multiple Myeloma
  • share-twitter-Commercial Launch of Rapid Diagnostic Device for Multiple Myeloma

Comment/Share

Chat now!